ANI releases Kionex Suspension
ANI Pharmaceuticals is introducing Kionex (Sodium Polystyrene Sulfonate Suspension) for Oral or Rectal use. Kionex Suspension is a commercially available therapeutic equivalent to SPS Suspension for Oral or Rectal use.
"The launch of Kionex Suspension for Oral or Rectal use exemplifies our capability to bring complex generics with limited market competition to our customers and patients in need. This launch is especially meaningful given the complexity of the development and is a testament to the tireless efforts of our strong R&D team to meet the updated guidance from the U.S. Food and Drug Administration,” said Nikhil Lalwani, president and CEO of ANI.
[Read more: ANI debuts generic Fleqsuvy]
Sodium Polystyrene Sulfonate Oral / Rectal Suspension had a market value of approximately $30.3 million, per March 2024 IQVIA data.
[Read more: ANI obtains FDA OK for generic Divigel]